Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis

Scandinavian Journal of Immunology

Volumn 48, Issue 2, 1998, Pages 201-211

  Tanaka, A ^a   Ohashi, Y ^a   Kakinoki, Y ^a   Nakai, Y ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC RHINITIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; DERMATOPHAGOIDES FARINAE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALLERGENS; ANTIGENS, DERMATOPHAGOIDES; CELLS, CULTURED; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-5; MALE; RHINITIS, ALLERGIC, PERENNIAL; TH1 CELLS; TH2 CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031843183     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00362.x     Document Type: Article

References (43)

1. Ricci M, Rossi O, Bertoni M, Matucci A. The importance of TH2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993;23:360-9.
2. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone; implication for immune regulation. Immunol Today 1987;8:223-7.
3. + T-cell subsets, differentiation and function. Res Immunol 1991;142:59-63.
4. Spiegelberg HL, Beck L, Stevenson DD, Ishioka GY. Recognition of T cell epitopes and lymphokine secretion by rye grass allergen Lolium perenne I-specific human T cell clones. J Immunol 1994; 152:4706-11.
5. Kay AB, Ying S, Varney VA et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775-8.
6. Robinson DS, Hamid Q, Ying S et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in asthma asthma. N Eng J Med 1992;326:298-304.
7. Rothemberg ME, Peterson J, Stevens RL, Silberstein DS. Mckenzie DT, Austen KF, Owen WF. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced variability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 1989;143: 2311-16.
8. Kay AB. Lymphocytes-T and their products in atopic allergy and asthma. Int Arch Allergy Immunol 1992;149:189-93.
9. Leung DYM, Geha RS. Regulation of the human IgE antibody response. Int Rev Immunol 1987;2:75-91.
10. Schleimer RP, Sterbinsky SA, Kaiser J et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992;148: 1086-92.
11. Ewan PW, Alexander MM, Snape C et al. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:501-8.
12. Corrado OJ, Pastorello E, Ollier S et al. A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac®) in patients with perennial rhinitis, 1. Clinical aspects. Allergy 1989;44:108-15.
13. McHugh SM, Lavelle B, Kemeny DM et al. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteroyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:521-32.
14. Ohashi Y, Nakai Y, Kakinoki Y et al. Immunotherapy affects the seasonal increase in specific IgE and interleukin-4 in the serum of patients with seasonal allergic rhinitis. Scand J Immunol 1997;46: 67-77.
15. + T cells from allergic individuals. J Exp Med 1993;178:2123-30.
16. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
17. Okuda M, Ishikawa T, Saito Y, Shimizu T, Baba S. A clinical evaluation of N′-5 with perennial-type allergic rhinitis. A test by multi-clinic, intergroup, doubleblind comparative method. Ann Allergy 1984;53:178-85.
18. 41st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990;24:606-9.
19. Ohashi Y, Ohno Y, Okamoto H et al. Clinical evaluation of lumiward immunoassay system for measurement of Japanese cedar pollen-specific IgE antibodies. Pract Otol 1996;89:575-81.
20. Tanaka K, Ishikawa E, Ohmoto Y, Hirai Y. In vitro production of human interleukin 1α and interleukin 1β by peripheral blood mononuclear cells examined by sensitive sandwich enzyme immunoassay. Eur J Immunol 1987;17:1527-30.
21. Kita M, Ohmoto Y, Hirai Y, Yamaguchi N, Imanishi J. Induction of cytokines in human peripheral blood mononuclear cells by mycoplasms. Microbiol Immunol 1992;36:507-16.
22. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89:955-8.
23. Ohashi Y, Nakai Y, Tanaka A et al. Ten years follow-up study of allergen-specific IgE and IgG4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients treated with immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998;47:167-78.
24. Yamaguchi Y, Hayashi Y, Sugama Y et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. J Exp Med 1988;167:1737-42.
25. Bittleman DB. Allergic models and cytokines. Am J Respir Crit Care Med 1994;150:s72-7.
26. Ohashi Y, Nakai Y, Tanaka A et al. Allergen-induced synthesis of interleukin-5, but not of IgE, is a key mechanism linked to symptomatic episodes of seasonal allergic rhinitis in sensitized individuals. Scand J Immunol 1998;47:596-602.
27. Mon A, Suko M, Tsuruoka N et al. Atopic diseases and eosinophil inflammation - possible management with agents which downregulate IL-5 gene transcription. Environ Dermatol 1994;1:42-54.
28. Oosterhout AJMV, Landenius ARC, Savelkoul HFJ, Ark IV, Delsman KC, Kijikamp FP. Effect of anti-IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993; 147:548-52.
29. Pene J, Rousset F, Briere F et al. Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen. Eur J Immunol 1988;18:929-35.
30. Maggi E, Parronchi P, Manetti R et al. Reciprocal regulatory effects of IFN-γ and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992;148:2142-7.
31. Tang MLK, Coleman J, Kemp AS. Interleukin-4 and interferon-gamma production in atopic and non-atopic children with asthma. Clin Exp Allergy 1995;25:515-21.
32. Beatrice F, Giordano C, Succo G, Vico F, Sacchi M, Sartoris A. Basal serum interferon-gamma production in hay fever patients. Clin Allergy 1988;18:411-12.
33. Ellaurie M, Yost SL, Rosenstreich DL. A simplified human whole blood assay for measurement of dust mite-specific gamma interferon production in vitro. Ann Allergy 1991;66:143-7.
34. Vercelli D, Geha R. The IgE system. Ann Allergy 1989;63:4-12.
35. Gauchat JF, Aversa G, Gascan H, Vries JE. Modulation of IL-4 induced germline ε RNA synthesis in human B cells by tumor necrosis factor-α, anti-CD40 monoclonal antibodies or transforming growth factor-β correlates with levels of IgE production. Int Immunol 1992;4:397-406.
36. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991; 9:27-35.
37. Ohashi Y, Tanaka A, Kakinoki Y et al. Effect of immunotherapy on seasonal changes in serum-specific IgE and IgG4 in patients with pollen allergic rhinitis. Laryngoscope 1997;107:1270-5.
38. Ohashi Y, Tanaka A, Kakinoki Y et al. Serum level of soluble interleukin-2 receptor in patients with seasonal allergic rhinitis. Scand J Immunol 1997;45:315-21.
39. Ohashi Y, Nakai Y, Tanaka A et al. Clinical role of soluble adhesion molecules during immunotherapy for perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg 1998;124:41-5.
40. Ohashi Y, Nakai Y, Okamoto H et al. Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Immunol 1996;43:680-6.
41. Durham SR, Varney VA, Ying S et al. Effect of grass pollen immunotherapy on cell infiltration and cytokine mRNA expression during allergen-induced late nasal responses (Abstract). J Allergy Clin Immunol 1994;93:230.
42. MacDonald SM, Naclerio RM, Hamilton RG et al. Cytokine measurements in patients receiving standard immunotherapy (Abstract). J Allergy Clin Immunol 1994;93:230.
43. O'Brien RM, Byron KA, Varigos GA et al. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy 1997;27:46-51.